ArticleScience translational medicine2023

An improved reporter identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor.

Oscar E Reyes Gaido et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.